Safety, pharmacokinetics, and efficacy of subcutaneous isatuximab in adults with warm autoimmune hemolytic anemia (wAIHA)

Trial Identifier: ACT16832
Sponsor: Sanofi
Start Date: September 2021
Primary Completion Date: June 2023
Study Completion Date: June 2023
Condition: Anemia

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
FRANCE Creteil Cedex, FRANCE, 94010
GERMANY Essen, GERMANY, 45147
ITALY, Milano Milano, ITALY, 20122
NETHERLANDS Leiden, NETHERLANDS, 2333 ZA
UNITED KINGDOM, London, City of London, London, City of, UNITED KINGDOM, NW1 2PG
UNITED STATES, Pennsylvania Philadelphia, Pennsylvania, UNITED STATES, 19111